Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 July 2021 to Question 35705 on Motor Neurone Disease: Drugs, if he will provide details of the projects relating to Motor Neurone Disease that were funded by the National Institute for Health Research in each of the years between 2015 and 2020.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The information requested is shown in the following table. The National Institute for Health Research (NIHR) is also funding research on motor neurone disease through the NIHR’s research infrastructure, including the NIHR Sheffield Biomedical Research Centre. However this information is not available at individual study level.
Year | Project |
2015/16 | Telehealth in Motor Neurone Disease: the TiM trial. A randomised controlled pilot study of the use of the TiM system to deliver highly specialised care to patients and carers of those living with motor neurone disease. * Evaluation of the clinical and cost-effectiveness of Short-term Integrated Palliative Care Services (SIPC) to OPTimise CARE for people with advanced longterm Neurological conditions (OPTCARE Neuro) * |
2016/17 | Head up: The development of a novel cervical orthosis to support neck weakness due to neurological disease. * Telehealth in Motor Neurone Disease: the TiM trial. A randomised controlled pilot study of the use of the TiM system to deliver highly specialised care to patients and carers of those living with motor neurone disease. * |
2017/18 | Telehealth in Motor Neurone Disease: the TiM trial. A randomised controlled pilot study of the use of the TiM system to deliver highly specialised care to patients and carers of those living with motor neurone disease. * Evaluation of the clinical and cost-effectiveness of Short-term Integrated Palliative Care Services (SIPC) to OPTimise CARE for people with advanced longterm Neurological conditions (OPTCARE Neuro) * A feasibility study and randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND) * |
2018/19 | Telehealth in Motor Neurone Disease: the TiM trial. A randomised controlled pilot study of the use of the TiM system to deliver highly specialised care to patients and carers of those living with motor neurone disease. * A feasibility study and randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND) * Nusinersen for treating infant or child spinal muscular atrophy [ID1069] A programme to develop and evaluate a complex intervention to achieve a high calorie diet for people with Amyotrophic Lateral Sclerosis (HighCALS) * Enhancing the efficacy of non-invasive ventilation for patients with motor neurone disease: Synthesising the evidence, mapping the services and translating the evidence into clinical practice. * |
2019/20 | A feasibility study and randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND) * A programme to develop and evaluate a complex intervention to achieve a high calorie diet for people with Amyotrophic Lateral Sclerosis (HighCALS) * Enhancing the efficacy of non-invasive ventilation for patients with motor neurone disease: Synthesising the evidence, mapping the services and translating the evidence into clinical practice. * Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473] - Part 1 |
2020/21 | A feasibility study and randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND) * A programme to develop and evaluate a complex intervention to achieve a high calorie diet for people with Amyotrophic Lateral Sclerosis (HighCALS) * Enhancing the efficacy of non-invasive ventilation for patients with motor neurone disease: Synthesising the evidence, mapping the services and translating the evidence into clinical practice. * Onasemnogene abeparvovec for treating spinal muscular atrophy type 1[ID1473] - Part 2 Risdiplam for treating spinal muscular atrophy [ID1631] |
Note:
* Project funded for multiple years spanning the period 2015-2020.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will hold discussions with the Chancellor of the Exchequer on increasing spending on targeted research on motor neurone disease ahead of the 2021 Spending Review.
Answered by Edward Argar - Minister of State (Ministry of Justice)
There are no plans for specific discussions. The Department funds research through the National Institute for Health Research (NIHR). It is not usual practice to ring-fence funding for particular topics or conditions. The NIHR welcomes funding applications for research into any aspect of human health, including motor neurone disease. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. We are currently working on ways to significantly boost further research on dementia and neurodegeneration at all stages, including medical and care interventions.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to respond to the correspondence of 25 February 2021 from the hon. Member for Rochdale on the legislative proposals for a Health and Care Bill.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We replied to the hon. Member on 3 September 2021.